Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis
Abstract Background High-dose methotrexate (HD-MTX) is a potent chemotherapeutic agent used to treat pediatric acute lymphoblastic leukemia (ALL). HD-MTX is known for cause delayed elimination and drug-related adverse events. Therefore, close monitoring of delayed MTX elimination in ALL patients is...
Main Authors: | Chang Jian, Siqi Chen, Zhuangcheng Wang, Yang Zhou, Yang Zhang, Ziyu Li, Jie Jian, Tingting Wang, Tianyu Xiang, Xiao Wang, Yuntao Jia, Huilai Wang, Jun Gong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | BMC Medical Informatics and Decision Making |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12911-023-02248-7 |
Similar Items
-
Case report: Intravitreal methotrexate in intraocular acute lymphoblastic leukemia
by: Matteo Pederzolli, et al.
Published: (2022-08-01) -
Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity
by: Marjan Abedi, et al.
Published: (2020-05-01) -
Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia
by: Xuan Gao, et al.
Published: (2021-07-01) -
Effect of methotrexate and doxorubicin cumulative doses on superoxide dismutase levels in childhood acute lymphoblastic leukemia
by: Khalida Fetriyani Ningsih, et al.
Published: (2015-10-01) -
Intravitreal methotrexate in type B lymphoblastic leukemia—Case Report
by: Maria Isabel Maya Naranjo, et al.
Published: (2023-08-01)